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Introduction 
 
As long ago as the beginning of the last century, psychiatrists recognized the 
possible association between schizophrenia and oestrogens (for review see 1). On 
the one hand, early clinicians such as Kraepelin (2) or Kretschmer (3) described 
signs of a chronic "hypooestrogenism" in women with schizophrenia. On the other 
hand, there have long existed observations indicating an association between 
oestrogen blood levels and acute psychotic symptomatology. Thus, acute psychosis 
seems to be ameliorated during physiological states such as pregnancy when 
oestrogen blood levels are high, but worsened during physiological states such as 
the postpartum period, the perimenstrual period, or menopause, when oestrogen 
blood levels are low. 
 
The oestrogen protection hypothesis 
 
Research of the last two decades has confirmed many of the historical observations 
concerning a protective effect of oestrogens in schizophrenia. And what is even more 
important, basic research has made important contributions to explain possible 
modes of action. 
 
To begin with, identification of oestrogen receptors in the limbic system has led to the 
assumption that oestrogens not only play a role in the modulation of endocrine 
functions, but must also have a "neuromodulating function" (for review see 1). In the 
early 1980s, it was also observed that the effect of oestrogens in laboratory animals 
is in some respects similar to that of neuroleptics. It has also been shown that 
oestrogens can modulate the sensitivity and number of dopamine receptors. It was 
 3
therefore hypothized that oestrogens exert their antipsychotic effects similarly to 
traditional neuroleptics, mainly by blockade of dopaminergic transmission. 
 
Today we know that oestrogens do not only modulate dopamine, but also serotonin, 
which is also thought to be relevant for schizophrenia and influence many other 
neurotransmitters and brain functions to such a degree that they have even been 
called "nature's psychoprotectant" (4). 
 
In addition, epidemiological studies on sex differences in schizophrenic disorders 
suggest that the physiologically high estradiol production in young fertile women 
contributes to the later age of onset in women as compared to men and also to the 
better course of the disease, especially in young women. Thus, different 
epidemiological studies show that, in women, the disease, on average, begins four to 
five years later than in men. In own studies, we found peaks of illness onset at age 
20 to 24 in men, but age 25 to 29 in women, and women also exhibited an additional 
smaller peak after age 45, i.e. when they start to loose their protection of oestrogens 
(5, 6). 
 
Clinically, psychotic symptomatology has been shown to grow worse pre- or 
perimenstrually, -i.e. in the low oestrogen phase of the cycle (7). During pregnancy, 
when estradiol levels are 200 fold higher than normal, chronic psychoses seem to 
improve, but there is a 20 fold excess of psychosis after delivery, when oestrogen 
levels suddenly drop to normal. Furthermore, women with schizophrenia in the fertile 
age group of 20 to 40 years, i.e. the time of the highest ovarian estradiol production, 
need lower doses of neuroleptics than men of comparable age or older women - 
even when body weight is controlled. Finally, early puberty is associated with a later 
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onset of schizophrenia (for review see 1, 8). That means physiological oestrogens 
may play a role in delaying the outbreak of the disease. 
 
In a clinical study, we examined 32 acutely admitted women with schizophrenia who 
gave a history of regular menstrual cycles. We saw a significant excess of 
admissions during the perimenstrual low oestrogen phase of the cycle, and, during 
the hospital stay of the 32 women, a significant association emerged between 
estradiol levels on one hand and different psychopathology scores on the other: 
psychopathology seemed to improve when estradiol levels rose, and vice versa (7). 
Interestingly, these patients showed many signs of a severely disturbed gonadal 
function with significantly lower estradiol and progesterone blood levels as compared 
to 29 controls with depressive disorders (9, 10). 
 
Well in line with our findings, Hallonquist et al. (11) observed lower symptom scores 
in women with schizophrenia during the mid-luteal as compared to the  early follicular 
phase of the menstrual cycle. They concluded that oestrogens may act as 
"endogenous neuroleptics". 
 
Further interesting results come from our study on late-onset schizophrenia (12). In 
this study on a large representative population of 267 first admitted patients, we 
found that there are not only twice as many women with onset over 40 as men, but 
they also suffer from a disease that is more severe as regards symptomatology and 
course as that of patients who fall ill early in life. One explanation for this could again 
be the loss of oestrogens. 
 
Intervention studies are one of the best ways to test the oestrogen protection 
hypothesis. They have a very long tradition. As early as in the 1940s, Manfred Bleuer 
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(13) reported the first unsystematic trials using a combination of ovarian and pituitary 
hormones. Mall (14), a German psychiatrist in charge of a large hospital, examined 
167 women suffering from schizophrenia with respect to oestrogen excretion in a 24-
hour-urine sample, basal temperature, and vaginal cytology. Based on his findings, 
he divided the psychoses into two groups:  hypofollicular and hyperfollicular. In the 
former group, he replaced oestrogens and found that "hypofollicular psychosis can 
be healed relatively easily by this substitution therapy". Unfortunately, Mall does not 
give many details about these interesting studies. 
 
Several contemporary investigators have now reported promising results using 
oestrogen as a therapeutic agent. Kulkarni et al. (15, 16) found that schizophrenic 
women receiving estradiol as an adjunct to neuroleptic treatment show more rapid 
improvement in psychotic symptoms than women receiving neuroleptics alone (see 
Kulkarni et al., this issue). Similar effects were reported by Lindamer et al. (17) in a 
case report of a postmenopausal woman. Recently, Lindamer et al. (18) reported on 
a community sample of women with schizophrenia. Twenty-four women received 
hormone replacement therapy; twenty-eight women had never received such 
therapy. Interestingly, the users of HRT needed a relatively lower average dose of 
antipsychotic medication and suffered from less severe negative symptoms. Ahokas 
et al. (19) demonstrated positive effects of oestrogen substitution in two women with 
postpartum psychosis. 
 
Implications for therapy and prophylaxis 
 
Recent studies thus seem to confirm the observations of the early clinicians: 
Schizophrenic psychosis seem to be influenced by oestrogens. Further research into 
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this area seems urgent and also very promising, as new therapeutic strategies could 
emerge that would benefit the many women worldwide suffering from schizophrenia. 
 
- One recommendation could be hormonal replacement with estradiol for women with 
schizophrenia during perimenopause as an augmentation strategy, an adjunct to 
neuroleptic medication. The dose of neuroleptics would be reduced and 
corresponding side effects minimized. To replace oestrogens in these women 
would at least attenuate perimenopausal complaints, which can contribute to a 
general deterioration of the mental state and, in vulnerable women, potentially 
provoke a psychotic episode. Oestrogen replacement therapy for women of this age 
group has been recommended for many reasons (20), but also seriously 
questioned recently, especially in its prophylactic use and in postmenopausal 
women of higher age groups (21-23). It has to be stressed in this connection, that 
there always should be an individual risk-benefit assessment. As for women with 
schizophrenia estradiol substitution could have additional benefits, further research 
on this potential additional indication is needed. 
 
- Research should also be done on the best mode of hormone replacement therapy 
for psychiatric patients. If replacement consists of an oestrogen-progestogen 
combination, the progestogen can antagonize the positive effects of oestrogens 
with respect to mental state (24). Furthermore, we have to consider the risks of 
oestrogens as shown e.g. recently by the Women’s Health Initiative Study (21-23), 
but also long-known risks such as endometrial and breast cancer. The newer 
synthetic steroids like tibolone seem to cause less endometrial proliferation. But 
their effects on the central nervous system are still not clear apart from the fact that 
they seem to have a mild androgenic effect and increase β-endorphin levels in the 
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pituary with improvement of mood and libido (25). Specific oestrogen receptor 
modulators (SERMS) of the second generation like raloxifene exert their main effect 
on bone. 
 
- In women suffering from frequent perimenstrual psychotic relapses "cycle-
modulated" neuroleptic therapy could be tried. However, this is a difficult regimen 
as regards compliance. Instead, especially if contraception is needed at the same 
time, monophasic contraceptive pills could be taken continuously (i.e. without 
intervals) in order to maintain a constant serum level of oestrogens (24). This 
requires a close cooperation between psychiatrists and gynaecologists and regular 
gynaecological visits. 
 
- In any case, oestrogens and the gonadal axis should in future be more seriously 
considered in the treatment of women with schizophrenia. Psychiatric history taking 
should always include questions regarding menstrual irregularities, amenorrhoea, 
loss of libido, anorgasmia, infertility, galactorrhoea. If there are any clinical 
suggestions of oestrogen deficiency, prolactin and oestrogen levels should be 
tested. 
 
- Hyperprolactinaemia can theoretically be caused by the disease itself and the 
accompanying stress, but also by neuroleptic treatment, and can lead to a 
secondary suppression of physiological oestrogen production. That means that 
many women with schizophrenia who take neuroleptics over years suffer from a 
partially "iatrogenic premature menopause" with all its potential short- and longterm 
consequences, as e.g. menopausal complaints or osteoporosis. In the case of 
hyperprolactinaemia with secondary oestrogen deficiency, atypical neuroleptics 
causing little or no hyperprolactinaemia (e.g. clozapine, quetiapine, aripiprazole or 
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olanzapine) are to be preferred. Otherwise oestrogens need to be added to the 
regimen. 
 
- The question of contraception always needs to be taken into account. Thus, with 
the change to atypical neuroleptics which do not produce hyperprolactinaemia, the 
menstrual cycle is normalized and fertility is regained, with a high risk of unplanned 
pregnancy. Women with schizophrenia may not wish to be mothers and, as well, 
the new neuroleptics may have unknown teratogenic potential. Therefore, when 
changing to an atypical neuroleptic, contraception counselling involving a 
gynaecologist should be initiated. 
 
- The interaction of neuroleptics with oestrogen preparations should always be 
considered. Thus, hormonal contraceptives can, for example, reduce metabolism of 
phenothiazine neuroleptics, which leads to an enhanced risk of side effects. On the 
other hand, certain neuroleptics can lead to reduced plasma levels of the 
contraceptive by hepatic enzyme induction, with the consequent risk of an 
unwanted pregnancy. This risk can be minimized by the continuous intake of a 
monophasic combined pill without a hormone free interval. Alternatively, an 
intrauterine device is a very reliable method of contraception. 
 
Finally, it must be emphasized that many of the mentioned strategies are still being 
researched. Thus, regarding intervention studies, results of larger controlled studies 
are needed before recommendations for a broad clinical application can be made. 
Furthermore, as has been stressed already, the decision must always be made on 
the basis of an individual risk/benefit assessment (21-23). Certain strategies, 
however, should be part of current standard clinical care. These include questions 
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regarding the gonadal axis as part of routine history taking and a close co-operation 
with the gynaecologist in the therapy of women with schizophrenia. 
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